Keyphrases
Adjuvant Chemotherapy
8%
Bevacizumab
10%
Brain Metastases
8%
Cancer Genome Atlas
17%
Cancer Types
17%
Carboplatin
20%
Chemotherapy
18%
Cisplatin
11%
Clinical Practice Guidelines
6%
Clinical Trials
9%
Confidence Interval
10%
Docetaxel
12%
Early-stage Lung Cancer
9%
Epidermal Growth Factor Receptor
8%
Erlotinib
8%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
7%
Gefitinib
6%
Genetic Modification
9%
Hazard Ratio
8%
Human Cancer
16%
In Cancer
18%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
46%
Lung Adenocarcinoma
13%
Lung Cancer
49%
Lung Squamous Cell Carcinoma
7%
Molecular Characterization
7%
NCCN Guidelines
7%
Non-small Cell Lung Cancer (NSCLC)
90%
Non-squamous Non-small Cell Lung Cancer
10%
Oncology
12%
Overall Survival
20%
Paclitaxel
7%
Pan-cancer Analysis
31%
Patient-derived Xenograft
7%
Pemetrexed
17%
Phase I Study
10%
Phase II Study
23%
Phase II Trial
16%
Platinum-based Chemotherapy
8%
Previously Treated
9%
Progression-free Survival
10%
Radiation Therapy
7%
Small Cell Lung Cancer
15%
Solid Tumors
7%
Stable Disease
8%
Stage III Non-small Cell Lung Cancer
7%
Targeted Therapy
16%
Tumor
32%
Tumor Subtype
8%
Whole Genome
32%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
5%
Adverse Event
9%
Bevacizumab
9%
Biological Marker
6%
Brain Metastasis
6%
Carboplatin
20%
Cetuximab
5%
Chemoradiation Therapy
7%
Chemotherapy
36%
Cisplatin
10%
Clinical Trial
12%
Diseases
26%
Docetaxel
11%
Epidermal Growth Factor Receptor
11%
Erlotinib
7%
Esophagus Cancer
5%
Etoposide
6%
Gefitinib
6%
Irinotecan
6%
Lung Adenocarcinoma
5%
Lung Cancer
46%
Malignant Neoplasm
25%
Maximum Tolerated Dose
6%
Neoplasm
22%
Non Small Cell Lung Cancer
100%
Overall Survival
24%
Paclitaxel
17%
Pemetrexed
14%
Phase II Trials
12%
Progression Free Survival
13%
Recurrent Disease
5%
Small Cell Lung Cancer
18%
Solid Malignant Neoplasm
9%
Survival Rate
5%
Medicine and Dentistry
Adjuvant Chemotherapy
6%
Arm
7%
Bevacizumab
7%
Biological Marker
6%
Brain Metastasis
5%
Cancer
12%
Cancer Types
7%
Carboplatin
9%
Chemoradiotherapy
5%
Cisplatin
5%
Clinical Oncology
6%
Clinical Trial
6%
Diseases
21%
Epidermal Growth Factor Receptor
6%
Immunotherapy
6%
Lung
6%
Lung Adenocarcinoma
9%
Lung Cancer
49%
Malignant Neoplasm
45%
Metastatic Carcinoma
7%
Neoplasm
29%
Non Small Cell Lung Cancer
77%
Oncology
12%
Overall Survival
18%
Paclitaxel
8%
Pemetrexed
13%
Positron Emission Tomography
6%
Progression Free Survival
6%
Radiation Therapy
9%
Recurrent Disease
7%
Small Cell Lung Cancer
17%
Somatics
5%
Squamous Cell Lung Carcinoma
6%
Surgery
6%
Targeted Therapy
13%
The Cancer Genome Atlas
8%